Clinical trials: Bladder Cancers
Colon Cancer, Gastric Cancer
Integrated Care Pathway in Oncology (PASSION)
A centralized unit for integrated management of care pathway in Oncology has been created. This unit settles the patients' appointments (biopsy, intravenous device, chemotherapy, imaging, oncologist...).
- Conditions
- Colon Cancer, Gastric Cancer, Pancreatic Cancer, Thoracic Neoplasms
- Trial name
- PASSION (NCT04235556)
- Testing
- Care pathway unit
- Where
- France
- Volunteers
- 1,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bladder Cancer
Effect of Fresh Gas Flow on Emergence Time
The purpose of this study is to evaluate the effect of fresh gas flow on emergence time in patients undergoing transurethral resection of bladder tumor.
- Trial name
- NCT05376631
- Testing
- Fresh gas flow of 5 L/min, Fresh gas flow of 10 L/min
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Asan Medical Center
Recurrent Colon Cancer, Recurrent Rectal Cancer
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
This pilot phase II studies how well computed tomography (CT) and positron emission tomography (PET) imaging works in detecting disease in patients undergoing surgery for metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV A Bladder Cancer, Stage IV A Rectal Cancer
- Trial name
- NCT01821105
- Testing
- PET Scan, CT Scan, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Bladder Cancer, Ureter Cancer
Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy
This study aims to verify superiority of pemetrexed maintenance to observation for patient without disease progression after 1 st line cisplatin-based chemotherapy.
- Conditions
- Bladder Cancer, Ureter Cancer, Transitional Cell Carcinoma
- Trial name
- PREMIER (NCT03193788)
- Testing
- pemetrexed, Folic Acid, Vitamin B12 Injection
- Where
- 21 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Asan Medical Center
Bladder (Urothelial, Transitional Cell) Cancer
Bladder Perfusion of Plasma-Activated Saline for Bladder Cancer
This preliminary clinical study evaluates the safety and initial efficacy of a novel therapy called Plasma-Activated Saline Solution (PASS) for bladder cancer patients.
- Trial name
- NCT07272603
- Testing
- Plasma-Activated Saline Solution (PASS) Bladder Instillation
- Volunteers
- 5 people
- Sponsor
- Qilu Hospital of Shandong University
Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
Background: Many cancers of the testicles and urinary tract are rare diseases; these are diseases that affect less than 200,000 people in the United States. It can be hard to study treatments for these diseases.
- Conditions
- Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors
- Trial name
- NCT06041503
- Testing
- Pembrolizumab, Enfortumab vedotin
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Muscle-invasive Urothelial Cancer of the Bladder
Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder
This trial is to assess the efficacy of pembrolizumab (MK3475) added to concurrent radiation and gemcitabine in the management of patients with muscle-invasive urothelial cancer who are not candidates for or decline radical…
- Trial name
- NCT02621151
- Testing
- Pembrolizumab, Transurethral Resection of Bladder Tumor, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
This phase II trial studies how well gemcitabine hydrochloride and eribulin mesylate work in treating patients with bladder cancer that has spread to other places in the body or cannot be removed by surgery.
- Conditions
- Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Ureter Cancer AJCC v7
- Trial name
- NCT02178241
- Testing
- Eribulin Mesylate, Gemcitabine Hydrochloride
- Where
- 18 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Urine-based Detection of Non-muscle Invasive Bladder
Non-muscle invasive bladder cancer (NMIBC), which comprises approximately 75% of bladder tumors, has the highest recurrence rate of all cancers, with around 70% of the patients developing local recurrences, despite elaborated…
- Trial name
- SOLUSION (NCT03962933)
- Where
- Denmark
- Volunteers
- 196 people
- Sponsor
- Nessn Azawi
Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients with BCG-unresponsive or BCG-exposed CIS NMIBC.
- Trial name
- ENHANCE (NCT06503614)
- Testing
- Durvalumab, Monalizumab
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- John Sfakianos
Bladder Cancer
Bladder Washing Cytology for Detection of Urothelial Carcinoma Using Catheter or Flexible Cystoscope: Which is Better?
Urine cytology can be collected with spontaneous urine or by washing the bladder. It is commonly accepted among urologist that instrumental bladder washing is the method of choice.
- Trial name
- BWash (NCT05643807)
- Testing
- Flexible cystoscopy, Urinary catheter
- Where
- Switzerland
- Volunteers
- 414 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Urinary Bladder Neoplasms
Prospective Sample Collection for Cancer of Bladder
The goal of the Flemish Databank for Urothelial Cancer is to collect clinical and pathological data of patients treated for urothelial cancer (UC).
- Trial name
- ProCaB (NCT03973671)
- Where
- Belgium
- Volunteers
- 300 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Bladder Cancer
A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology
The investigators are here to invite participants to participate in a medical research project, and this informed consent form provides participants with information to decide whether or not to participate in this study.
- Trial name
- NCT06662071
- Testing
- Organoid culture
- Where
- 17 sites in China
- Volunteers
- 293 people
- Sponsor
- Qilu Hospital of Shandong University
Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
We will combine an oral investigational vascular endothelial growth factor (VEGF inhibitor) called pazopanib which is being studied in kidney cancer will be combined with standard chemotherapy called taxol in patients with…
- Conditions
- Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
- Trial name
- NCT01108055
- Testing
- Pazopanib (GW786034), Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Sandy Srinivas
Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-DWJ155 and the safety and imaging properties of [68Ga]Ga-DWJ155 in patients with…
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
- Trial name
- NCT07660055
- Testing
- [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
- Where
- 6 sites in United States, Australia and 2 more
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Cystoprostatectomy Versus Radiotherapy Combined With ADT for the Treatment of cT4 Prostate Cancer With Bladder Invasion
Prostate cancer is the most common male cancer in global, which accounts for 19% of the total and poses great hazards to male health.
- Trial name
- CRADT (NCT03482089)
- Testing
- Cystoprostatectomy, external beam radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Tongji Hospital
Oncology, Bladder Cancer
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high…
- Conditions
- Oncology, Bladder Cancer, Superficial Bladder Cancer, Recurrence
- Trial name
- NCT03121768
- Where
- Egypt
- Volunteers
- 761 people
- Sponsor
- Mansoura University
Bladder Cancer
Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00777491
- Testing
- induction cisplatin, induction 5-fluorouracil, induction gemcitabine
- Where
- 11 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Radiation Therapy Oncology Group
Bladder Cancer
Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors
This clinical study is designed to evaluate the diagnostic performance of VisioCyt test, which would improve the early diagnosis of bladder cancer in order to optimize the management of individual patients as part of a cancer…
- Trial name
- VISIOCYT 1 (NCT02966691)
- Testing
- VisioCyt® diagnostic test
- Where
- 14 sites in France
- Volunteers
- 1,360 people
- Sponsor
- Vitadx
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.